Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >
Prior to joining Sagient Research, John Tucker was the director of medical chemistry for ChemBridge Corp. and before that served as principal scientist for Elan Corp. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV, antibacterials and Alzheimer's disease. Tucker received his doctorate in organic chemistry from UCLA, working in the research group of Nobel Laureate Donald Cram. Tucker also earned his master's degree in business administration from the Anderson School of Management at UCLA.
Lessons from the Liver Meeting: Sagient's John Tucker Names Companies that Could Reignite the Hepatitis C Industry (11/29/12) The hepatitis C (HCV) market was white hot in 2011 and through the beginning of 2012, but investors have gotten the message that new HCV drugs are not going to rival cancer and cardiovascular drugs for profits. In this interview with The Life Sciences Report, analyst John Tucker of Sagient Research discusses a handful of stocks that could benefit from new, patient-friendly HCV therapies with enough revenue to propel shares upward.
"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >
"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >